Double Blind Study of Trp01 in Patients With Alzheimer's Disease

September 13, 2005 updated by: Queen's University

Double Blind Medium Term Efficacy Study of Trp01 in Patients With Mild to Moderate Alzheimer's Disease

The purpose of this study is to determine whether tryptophan is effective in the treatment of mild to moderate Alzheimer's Disease (AD).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The clinical trial will be a double-blind, placebo-controlled study with patients being randomized in a 2:1 ratio into groups A and B, respectively:

Group A: TRP01 1g b.i.d. for 26 weeks

Group B: placebo capsules b.i.d. for 26 weeks

After the initial screening, clinic visits will take place at 0, 13 and 26 weeks. The blinding will be maintained until all patients have completed the 26-week trial. Any patients wishing to continue taking the medication upon completion of the trial will be provided a prescription for the drug and may purchase it at their own expense.

Study Type

Interventional

Enrollment

12

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Kingston, Ontario, Canada, K7L 3N6
        • Queen's University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Patients will be selected in order to fulfill both of the following definitions:

  • Dementia according to DSM-IV criteria :

    • development of multiple cognitive deficits manifested by both memory impairment and one or more of the following cognitive disturbances: aphasia, apraxia, agnosia, disturbance in executive functioning
    • the above-mentioned deficits cause significant impairment in social or occupational functioning
    • they do not occur exclusively during the course of delirium

  • Dementia according to communicative disorders and stroke criteria (NINCDS-ADRDA)

    • dementia established clinically and documented by a Folstein Mini-Mental State Examination (MMSE)
    • deficits in two or more areas of cognition
    • progressive worsening of memory and other cognitive functions
    • no disturbance of consciousness
    • absence of systematic disorders or other brain diseases that in and of themselves can account for progressive deficit in memory and cognition

Furthermore, patients must fulfill the following criteria:

  • men, or postmenopausal or surgically sterilized women
  • with severity of dementia of mild to moderate degree as reflected by a score of greater than 14 but less than 26 on the MMSE
  • with a minimum one-year duration of the symptomatology (progressive worsening of memory and other cognitive functions)
  • living at home or in an institution provided that they have reliable caregivers
  • able to perform the required psychometric tests and evaluations. Visual and auditory acuity (with glasses or hearing aid if required) must be sufficient to complete the protocol-specified procedures.
  • Clinical laboratory battery (see section 7.2.2) must yield results within normal limits or determined as not clinically significant by the study physician for the patient's sex and age
  • Patients and their substitute decision-makers must have signed the written informed consent form

Exclusion Criteria:

Patients with any of the following will not be included in the study:

  • Patients with any other cause of dementia as evidenced by medical history, general physical and neurological examination, laboratory tests, and neuroradiological findings:

    • Vascular dementia, as evidenced by Modified Hachinski Ischemia Scale
    • Depressive pseudementia, as evidenced by cognitive disturbances concomitant to a major depressive episode according to DSM-IV and/or a history of more than one major depressive episode
    • DSM-IV criteria for any major psychiatric disorder including schizophrenia, alcohol or substance abuse
    • Huntington's chorea or Parkinson's disease, evidenced by neurological examination, with an onset prior to or concurrent with dementia
    • Creutzfeldt-Jakob disease
    • Intracranial mass lesion
    • Clinically important head injury
    • History or current evidence of stroke
    • Onset of dementia following cardiac arrest or heart surgery
    • Neurosyphilis
    • Seropositivity for HIV
    • Vitamin B12 deficiency
    • Uncorrected hypothyroidism (i.e. abnormal free T4, ultrasensitive TSH)

  • Patients with other relevant concomitant diseases:

    • Patients with history or current evidence of a sleep disorder
    • Patients with a clinically significant cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, opthalmologic, or hematologic condition
    • Current evidence or history within the past year of myocardial infarction (MI), congestive heart failure
    • Blood pressure at screening of > 180 mm Hg systolic or 100 mm Hg diastolic
    • Impaired renal, hepatic, or gastrointestinal function, which could interfere with drug absorption, metabolism or excretion
    • Seizure disorder
    • Diabetes
    • Earlier diagnosis or current evidence of cataracts
    • Progressive fatal disease (other than AD)
    • Treatment with any other investigational drug in the last 8 weeks prior to screening
    • Previous administration of TRP01

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
1. MMSE score
2. Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-Cog) as an evaluation of cognitive functioning

Secondary Outcome Measures

Outcome Measure
1. Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)
2. Neuropsychiatric Inventory (NPI)
3. Disability Assessment for Dementia (DAD)
4. Physical Self-Maintenance Scale (PSMS)
5. Functional Activities Questionnaire (FAQ)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Queen's University

Investigators

  • Study Chair: Donald F Weaver, MD, PhD, Queen's University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2001

Study Completion

March 1, 2002

Study Registration Dates

First Submitted

September 13, 2005

First Submitted That Met QC Criteria

September 13, 2005

First Posted (Estimate)

September 20, 2005

Study Record Updates

Last Update Posted (Estimate)

September 20, 2005

Last Update Submitted That Met QC Criteria

September 13, 2005

Last Verified

November 1, 2002

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DFW-TRP01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer's Disease

Clinical Trials on Tryptophan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe